[Liquid brucellar allergen in the combined treatment of brucellosis patients]

The efficacy of liquid brucellar allergen (LBA) was studied in 227 brucellosis patients with active infectious process and marked DTH, in need of a pathogenetically based decrease of specific infectious allergic background. The reference group was made up of 140 brucellosis patients given only basic therapy (antibiotics, antiinflammatory and symptomatic agents). The administration of LBA, whose active principle is a polysaccharide and protein complex, reduced high sensitivity to brucellar antigen and raised the functional activity of neutrophilic granulocytes and T-lymphocytes, improved the late results of the treatment of patients with brucellosis running its course with pronounced sensitization.